Endometriosis · Medical Management

Immunology and Immunotherapy of Endometriosis

Maksym RB, Hoffmann-Młodzianowska M, Skibińska M, Rabijewski M, Mackiewicz A, Kieda C

Published December 15, 2021 Journal of Clinical Medicine, 10(24), 5879
DOI 10.3390/jcm10245879 PMID 34945174 PMC PMC8708975

RRM Academy Synopsis

Removing endometriosis lesions is the top cause-based treatment

A 2021 review says removing the lesions is the best treatment of the cause. Selective immunotherapy cannot yet be used in routine care. Most immune research on endometriosis is in animals. Removal also eases the immune disorders.

Key Findings

  • Roughly 2–10% of women of reproductive age have endometriosis. The authors consider an altered immune reaction the main driver of the faulty immune surveillance that leads to it.
  • Among patients with the best prognoses on the endometriosis fertility index, up to 74.9% ± 4.2% conceive naturally within three years after radical removal of lesions.
  • Olive baboons with spontaneous endometriosis given immunosuppressive drugs developed larger lesions and a more advanced stage. Lesions showed at least a partial remission after the drugs were stopped.
  • In rats given an experimental vaccine, the chance of inducing endometriosis dropped from 69.6% to 4.3%. The animals received the vaccine before induction.
  • Luteinized unruptured follicle syndrome hits up to 30% of cycles in women with endometriosis, against 6% in healthy women. Among women with ovarian endometriomas, it may affect over 50% of cycles.

Interpretation

This is a literature review by Polish and French authors synthesizing earlier research on endometriosis immunology. The authors identify radical lesion removal as the most effective causative treatment for pain and infertility. They describe ethiodized oil flushing and G-CSF as supported by numerous publications. The authors note that many of the animal models used are not fully reliable and that human studies remain few. The findings support larger human studies of immune-based approaches to endometriosis.

RRM Context

The authors call lesion removal the most effective causative treatment for pain and infertility. RRM shares that root-cause logic: excision treats the source of the immune problem. The authors call the baboon study a significant warning that indiscriminate immune treatment may aggravate endometriosis. Adenomyosis, they add, cannot be removed without harming the uterus.

Abstract

Endometriosis is one of the most common gynecological and systemic diseases, with a remarkable immune background. Patients suffer from pain and fertility reduction. Due to the distinct immune component, an immunotherapeutic approach may gain importance in the future. In endometriosis, shifts in the cell fractions of the immune system are well known. Moreover, hypoxia concomitant with inflammation causes a disturbed immune response. The removal of endometriosis has a therapeutic effect, normalizes the immune disorders, and remains the most effective causative treatment in terms of pain and infertility. A key issue is whether a similar effect can be achieved for fertility with non-invasive immunotherapy where surgery is inadvisable or cannot be performed for various reasons. Numerous immunotherapy trials, including vaccines, were conducted on animals only, although the research is encouraging. Among the promising methods of non-specific immunotherapy is the administration of an ethiodized oil contrast. Moreover, due to the significant successes of immunotherapy in oncology, the possibility of immunotherapy affecting NK cells has been postulated. NK cells are responsible for the surveillance and apoptosis of ectopic cells. Expanding the arsenal of endometriosis treatment by immunotherapy is promising due to the significant contribution of immunological factors and the limitations of current treatment methods.

Read the guide

Topics

By this author

Related research

Endometriosis › Medical Management › Pain Management · General Gynecology › Pelvic Pain › Chronic Pelvic Pain · Genetics and Immunology › Reproductive Immunology › Inflammation and Reproduction
Radosław B Maksym, Marta Hoffmann-Młodzianowska, Milena Skibińska, Michał Rabijewski, Andrzej Mackiewicz, Claudine Kieda
R Maksym, M Hoffmann-Młodzianowska, M Skibińska, M Rabijewski, A Mackiewicz, C Kieda
PMID 34945174 34945174 DOI 10.3390/jcm10245879 10.3390/jcm10245879 Maksym et al. 2021, Maksym 2021